Oslo, December 9, 2025 - Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson's Care with Simplified and Precise Dosing for Personalized Treatment

Navamedic ASA has launched Flexilev® in the OraFID® single‑use dosing dispenser for personalized levodopa delivery in Parkinson’s patients, with prescriptions to be available at pharmacies in late December/early January; the device aims to reduce under‑ or overdosing by enabling precise, on‑demand adjustments to address motor fluctuations and end‑of‑dose gaps. Navamedic will lead the launch and marketing in Sweden, Norway and Denmark, while Orion Corporation has exclusive rights to market, distribute and sell the product across 27 European countries and will serve as the marketing‑authorization holder in its territory. The tie‑up gives Navamedic a pathway to scale the offering across Europe via Orion’s commercial network, potentially expanding Navamedic’s Scandinavian footprint and product reach in the neurological therapeutics market.

Analysis

Navamedic ASA announced the launch of Flexilev® in the OraFID® single-use dosing dispenser for levodopa, with prescriptions expected to be available at pharmacies in late December/early January; the product is positioned to enable on-demand, precise dosing to address motor fluctuations and end-of-dose gaps in Parkinson’s patients. The combination of minitablet drug and dispenser is marketed as a tool to reduce under- and overdosing and associated side effects, and management frames the initiative as a personalized-treatment solution for advancing Parkinson’s care.

Navamedic will lead the launch and marketing in Sweden, Norway and Denmark while Orion Corporation has been granted exclusive rights to market, distribute and sell the product across 27 European countries and will act as the marketing-authorization holder in its territory. Orion’s scale is highlighted by its 2024 net sales of EUR 1,542 million and ~3,700 employees, implying a credible commercial partner able to execute wide European roll-out and regulatory responsibilities.

The partnership creates a clear pathway to scale the offering beyond Scandinavia, but the announcement provides no pricing, reimbursement, or uptake data; commercial success depends on physician adoption, payor coverage and Orion’s execution of MA-holder obligations. Key near-term indicators to watch are initial prescription volumes in Scandinavia, any disclosed commercial terms or milestones with Orion, and reimbursement/market access developments in the 27-country territory.

Key Decisions for Investors

• Monitor initial prescription uptake and pharmacy-level sales in Sweden, Norway and Denmark after the late-December/early-January launch as the primary near-term commercial readout
• Seek disclosure or confirmation of commercial terms, revenue-sharing, upfront or milestone payments from the Orion agreement to model potential revenue upside for Navamedic
• Track regulatory, reimbursement and formulary outcomes in the 27 European countries where Orion is MA holder, since payor decisions will determine scalability and timing of material revenues
• Maintain a cautious operational stance until concrete sales or milestone data emerge — consider a limited or watch-only position pending early uptake metrics and any financial guidance from Navamedic